GYKI 47261 dihydrochloride
Non-competitive AMPA receptor antagonist (IC50 = 2.5 μM). Displays broad spectrum anticonvulsive activity and neuroprotective effects in vivo.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 395.71. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.53 mL||12.64 mL||25.27 mL|
|5 mM||0.51 mL||2.53 mL||5.05 mL|
|10 mM||0.25 mL||1.26 mL||2.53 mL|
|50 mM||0.05 mL||0.25 mL||0.51 mL|
References are publications that support the products' biological activity.
Abraham et al (2000) New non competitive AMPA antagonists. Bioorg.Med.Chem. 8 2127 PMID: 11003158
Bibbiani et al (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp.Neurol. 196 422 PMID: 16203001
If you know of a relevant reference for GYKI 47261 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: GYKI 47261 dihydrochloride, supplier, Non-competitive, AMPA, antagonists, Glutamate, Receptors, iGluR, Ionotropic, GYKI47261, dihydrochloride, AMPA, Receptors, AMPA, Receptors, Tocris Bioscience
Citations for GYKI 47261 dihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for GYKI 47261 dihydrochloride. Do you know of a great paper that uses GYKI 47261 dihydrochloride from Tocris? If so please let us know.
Reviews for GYKI 47261 dihydrochloride
There are currently no reviews for this product. Be the first to review GYKI 47261 dihydrochloride and earn rewards!
Have you used GYKI 47261 dihydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.